Rigosertib in myelodysplastic syndromes (MDS)
Explore this paper's citation graph
Summary
The Phase III study failed to meet the primary endpoint but clearly showed significant improvement in survival in a subset of very high risk MDS patients who were primary HMA failures, and a new Phase III trial designed to validate these findings is now ongoing.
- Type
- article
- Published
- 2016-07-28
- Cited by
- 2
- References
- 34
- OpenAlex
- https://openalex.org/W2492182383
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:57519254
Keywords
Myelodysplastic syndromes, Medicine, Lenalidomide, Context (archaeology), Clinical trial
References
- International scoring system for evaluating prognosis in myelodysplastic syndromes.
- RAS mutations in preleukaemias.
- Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy
- How we treat higher-risk myelodysplastic syndromes.
- Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
- Myelodysplastic syndromes
- Discovery of a Clinical Stage Multi Kinase Inhibitor Sodium (E)-2-2-Methoxy-5-[(2′, 4′, 6′-trimethoxystyrylsulfonyl)methyl]phenylaminoacetate (ON 01910.Na): Synthesis, Structure Activity Relationship and Biological Activity
- The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes
- Clinical and biological implications of driver mutations in myelodysplastic syndromes.
- Phase I Clinical Trial of Oral Rigosertib in Patients with Myelodysplastic Syndromes
- CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins.
- Molecular mechanisms involved in the progression of myelodysplastic syndrome.
- Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
- Treatment of Higher Risk Myelodysplastic Syndrome Patients Unresponsive to Hypomethylating Agents with ON 01910.Na
- Developments in the treatment of transfusion- dependent anemia in patients with myelodysplastic syndromes: epidemiology, etiology, genetics, and targeted therapies
- Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome
- Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
- Clinical Effect of Point Mutations in Myelodysplastic Syndromes
- Directed Therapy for Patients with Myelodysplastic Syndromes (MDS) by Suppression of Cyclin D1 with ON 01910.Na
- Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways.
Cited by
Related papers
- Research progress of decitabine in myelodysplastic syndromes
- Hypomethylating agents in the treatment of myelodysplastic syndromes and myeloid leukemia.
- Management of Cytopenias During Treatment with Lenalidomide in Patients with Myelodysplastic Syndromes
- Efficacy of lenalidomide in myelodysplastic syndromes.
- Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes.
- Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.
- 5-Azacytidine and Decitabine Monotherapies of Myelodysplastic Disorders
- New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
- Lenalidomide for treatment of myelodysplastic syndromes.